AIHealthcare

Absci is a clinical‑stage, **data‑first generative AI drug creation company** that combines **generative AI models with synthetic biology and scalable wet‑lab technologies** to design and optimize novel biologics—especially antibodies—against difficult‑to‑drug targets, aiming to get better therapeutics to patients faster. Its Integrated Drug Creation™ platform designs antibodies *de novo* (“from scratch” on a computer), then rapidly validates them in high‑throughput wet labs, supporting both an internal pipeline (e.g., ABS‑201 for androgenetic alopecia and endometriosis) and partnerships with major pharma, biotech, tech, and academic institutions.